© 2022 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
August 31, 2008
The SORT OUT II trial showed that the first generation of drug-eluting stents, Cypher® and Taxus®, exhibit similar efficacy and safety when used for percutaneous coronary intervention in everyday practice, including in a high proportion of off-label situations.
Wonder Drake, MD: Sarcoidosis is a Disease of Exclusion
FDA Approves Dupilumab for Eosinophilic Esophagitis
New 52-Week Data Finds Guselkumab Well Tolerated in Moderate to Severe Psoriasis